Vericel Corp Ord (VCEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.91B
Last updated: Nov 17, 2026 at 4:10 PM ET
Vericel Corp Ord (VCEL) Stock Chart
Vericel Corp Ord (VCEL) has a latest price of $57.88 on Nov 17, 2026, 3.1% below its 52-week high of $59.75. Its price rose 45.2% over the past 12 months. The month-end price rose 1,730.0% over the 10 years through Oct 2026, a compound annual rate of 33.7%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $62.42 in Apr 2021 and its lowest $2.20 in Oct 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart VCEL with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for VCEL.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 32.8%, and over 6 months it rose 67.8%. The month-end price rose 14.4% over the 3 years through Oct 2026, a compound annual rate of 4.6%.
| Period | Change |
|---|---|
| 1 month | +43.4% |
| 3 months | +32.8% |
| 6 months | +67.8% |
| 12 months | +45.2% |
| 12 months, with dividends | +45.2% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +14.4% | +4.6% |
| 5 years | -12.5% | -2.6% |
| 10 years | +1,730.0% | +33.7% |
Price by Year
Its best calendar year was 2018, when the price rose 219.3%, and its weakest was 2025, when it fell 34.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $40.26 | +11.8% |
| 2025 | $36.01 | -34.4% |
| 2024 | $54.91 | +54.2% |
| 2023 | $35.61 | +35.2% |
| 2022 | $26.34 | -33.0% |
| 2021 | $39.30 | +27.3% |
| 2020 | $30.88 | +77.5% |
| 2019 | $17.40 | 0.0% |
| 2018 | $17.40 | +219.3% |
| 2017 | $5.45 | +81.7% |
Trading Range
The price is 33.0% above its 50-day average of $43.51 and 46.1% above its 200-day average of $39.62.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $57.88 | |
| 52-week high | $59.75 | -3.1% |
| 52-week low | $28.95 | +99.9% |
| 50-day average | $43.51 | +33.0% |
| 200-day average | $39.62 | +46.1% |
Price Risk
Over 3 years, its largest fall from a peak was 52.5%.
| Measure | Value |
|---|---|
| 1-year beta | 0.49 |
| Largest fall, 1 year | -31.0% |
| Largest fall, 3 years | -52.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About VCEL
What is VCEL's 1-year price change?
Vericel Corp Ord's price rose 45.2% over the past 12 months. With dividends included, the 12-month total return was 45.2%.
What is VCEL's 5-year price change?
Vericel Corp Ord's month-end price fell 12.5% over the 5 years through Oct 2026, a compound annual decline of 2.6%. These figures leave out dividends.
What is VCEL's 52-week high and low?
Vericel Corp Ord's 52-week high is $59.75 and its 52-week low is $28.95. Its latest price of $57.88 on Nov 17, 2026 is 3.1% below the high.
What is VCEL's beta?
Vericel Corp Ord's 1-year beta against the S&P 500 is 0.49, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 31.0%.
Is the VCEL chart free?
Yes. Advanced Charting for VCEL is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
VCEL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors